Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Therapeutics, Inc. (NASDAQ: RCEL) announced a change in the date of its Q1 2021 earnings release and conference call to November 10, 2020. The conference call will occur at 1:30 p.m. Pacific time, where the company will discuss financial results and recent highlights. AVITA focuses on regenerative medicine, developing autologous skin restoration technologies like the RECELL System, approved by the FDA for treating acute thermal burns. The company emphasizes its innovative treatment solutions and aims to address unmet medical needs in burns and chronic wounds.
AVITA Therapeutics, Inc. (NASDAQ: RCEL) announced the adjournment of its 2020 Annual Stockholder Meeting originally scheduled for October 29, 2020, due to a lack of quorum. Only 49% of shares were represented, falling short of the required 50% majority. The meeting has been rescheduled for November 9, 2020, to gather more votes. During this time, the company is actively soliciting votes with the help of a proxy solicitor. Stockholders who have not yet voted are encouraged to do so by November 5, 2020. The company may incur additional costs if a quorum is not achieved at the adjourned meeting.
AVITA Therapeutics (NASDAQ: RCEL) announced its participation in two upcoming investor conferences: the Oppenheimer Fall MedTech Summit on November 12, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 8:30 a.m. ET. The company specializes in regenerative medicine, focusing on skin restoration using its patented RECELL System, approved by the FDA in September 2018 for treating acute thermal burns. AVITA is actively addressing various unmet medical needs in burns, chronic wounds, and aesthetics.
AVITA Therapeutics (NASDAQ: RCEL) announced its plans to release Q1 2021 financial results on November 11, 2020, after market close. A conference call to discuss these results will follow at 1:30 PM Pacific time. The company focuses on regenerative medicine, particularly with its RECELL® System for treating burns, which received FDA approval in September 2018. This system significantly reduces donor skin requirements and has been used in over 8,000 patients worldwide.